SciELO - Scientific Electronic Library Online

 
vol.57 número8Crise celíaca em paciente adulto com diabetes melito tipo 1: uma manifestação rara da doença celíacaAcompanhamento de caso de tiroidite subaguda com absorção incomum de 99mTc pela tiroide índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

Compartilhar


Arquivos Brasileiros de Endocrinologia & Metabologia

versão On-line ISSN 1677-9487

Resumo

ARAUJO, Rogério Santiago; RAMOS, André de Paula Silva  e  BORGES, Máriton de Araújo Sousa. Bezafibrate in an infant with congenital generalized lipodystrophy and severe hypertriglyceridemia. Arq Bras Endocrinol Metab [online]. 2013, vol.57, n.8, pp.653-658. ISSN 1677-9487.  https://doi.org/10.1590/S0004-27302013000800012.

Congenital generalized lipodystrophy (CGL) with severe hypertriglyceridemia in a children less than 1 year of age is associated with worse metabolic risk. We used data from patient records, as well as extensive literature research to write the manuscript. We report the case of an infant with typical phenotype of CGL and hypertriglyceridemia of 1,360 mg/dL who was treated with bezafibrate at a dose of 30 to 60 mg/day from age 11 months to 5.5 years old, with a measurement of nadir of triglycerides of 55 mg/dL. Clinical evolution and clinical laboratory tests before and after bezafibrate were carried out over 5 years and 6 months. Phenotype was classified as CGL type 2. Despite the efficient control of hypertriglyceridemia and absence of development of diabetes mellitus, the use of bezafibrate did not prevent the onset of hepatic steatosis during evolution. Hypolipidemic therapy with bezafibrate proved effective in maintaining the levels of triglycerides, cholesterol and its fractions at normal levels, and its use was not correlated with severe side effects during the described period.

        · resumo em Português     · texto em Português     · Português ( pdf )

 

Creative Commons License Todo o conteúdo deste periódico, exceto onde está identificado, está licenciado sob uma Licença Creative Commons